A Phase 2 clinical trial evaluating icatibant, titled "Hemodialysis-Induced Hypotension Therapy for End Stage Kidney Disease," was updated to completed status as of June 29, 2026.
The trial, registered under identifier NCT05297786, investigated icatibant in patients with end stage kidney disease experiencing hemodialysis-induced hypotension. It was conducted as a Phase 2 study.
The current status listed for this trial is COMPLETED. No results or outcome data are included in this update. This brief reports only the change in trial status and does not describe any efficacy or safety findings, since none were provided with this update.
Icatibant is an approved compound. This trial update reflects a milestone in its clinical investigation for a use in hemodialysis-related hypotension, separate from its approved indication.
Readers interested in additional detail on this study can consult the official trial registry listing for NCT05297786. For more background on icatibant generally, see the compound overview.